No abstract available.
Hypercholesterolemia* ; Lipoprotein-X* ; Lipoproteins*

PURPOSE: Growth hormone(GH) is a powerful inhibitor of lipoprotein lipase and is known to decrease fat cell mass. The lipolytic effect has more pronounced influence on visceral fat than subcutaneous fat. The effects of GH therapy on GH receptor in fat tissue are not clear. We investigated the changes in fat tissue and GH receptor mRNA in adipose tissue with GH therapy. METHODS: Eight children with growth hormone deficiency(GHD) and 9 children with Prader-Willi syndrome(PWS) were studied. The children were treated with 0.6U/kg/week GH for 6 months. We compared fat distribution on CT scan before and after GH therapy. Abdominal fat biopsy was done in 6 children with GHD, 3 children with PWS and 3 controls before and after GH therapy. GH receptor expression by reverse transcription PCR was examined. RESULTS: In children with GHD, total, subcutaneous and visceral fat were decreased after GH therapy(P>0.05), but thigh muscle mass was increased from 6,165 to 7,689(P<0.05). In chidren with PWS, visceral fat was decreased from 7,613 to 5,022 in abdominal CT(P<0.05) and V/S ratio(visceral fat/subcutaneous fat) was decreased also from 0.37 to 0.23(P<0.05). The thigh muscle mass was increased from 6,358 to 7,175. The expressions of GH receptor mRNA were reduced in children with GHD and PWS. But it was not significant in children with PWS. CONCLUSION: In children with PWS, fat mass was reduced and muscle mass was increased after GH therapy. In children with GHD, muscle mass was increased significantly and fat mass was decreased insignificantly. We observed down regulation of GH receptor of adipose tissue in patients with GHD after GH therapy.
Abdominal Fat ; Adipocytes ; Adipose Tissue ; Biopsy ; Child ; Down-Regulation ; Growth Hormone* ; Humans ; Intra-Abdominal Fat ; Lipoprotein Lipase ; Polymerase Chain Reaction ; Receptors, Somatotropin* ; Reverse Transcription ; RNA, Messenger ; Subcutaneous Fat ; Thigh ; Tomography, X-Ray Computed

BACKGROUND/OBJECTIVES: Endoplasmic reticulum (ER) stress is positively associated with atherosclerosis via elevating macrophage cell death and plaque formation, in which oxidative stress plays a pivotal role. Antioxidative, lipid-lowering, and anti-atherogenic effects of kimchi, a Korean fermented vegetable, have been established, wherein capsaicin, ascorbic acid, quercetin, 3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid, and lactic acids were identified. In this study, mechanisms of action of kimchi methanol extracts (KME) on fatty streak formation via suppression of ER stress and apoptosis in aorta were examined in low-density lipoprotein receptor knockout mice. MATERIALS AND METHODS: Mice fed a high cholesterol diet with an oral administration of KME (KME group, 200 mg·kg-bw⁻¹·day⁻¹) or distilled water (control group) for 8 weeks (n = 20 for group). Plasma lipid and oxidative stress levels were evaluated. Protein expression was measured by western blot assay. Fatty streak lesion size and the degree of apoptosis were examined in the aorta. RESULTS: Compared to the control group, in the KME group, plasma lipids levels were decreased and oxidative stress was alleviated (P < 0.05). Protein expression levels of nuclear factor (erythroid-derived 2)-like 2-mediated antioxidants in aorta were increased whereas those for ER stress markers, glucose regulated protein 78, phospho-protein kinase RNA-like ER kinase, phospho-eukaryotic initiation factor 2 subunit α, X-box binding protein 1, and C/EBP homologous protein were decreased in the KME group (P < 0.05). Moreover, apoptosis was suppressed via downregulation of phospho-c-Jun N-terminal kinase, bcl-2-associated X protein, caspases-9, and -3 with a concomitant upregulation of anti-apoptotic protein, B-cell lymphoma 2 (P < 0.05). Fatty streak lesion size was reduced and the degree of apoptosis was less severe in the KME group (P < 0.05). CONCLUSIONS: In conclusion, antioxidant activity of KME might prevent fatty streak formation through, in part, inhibition of ER stress and apoptosis in aortic sinus where macrophages are harbored.
Administration, Oral ; Animals ; Antioxidants ; Aorta* ; Apoptosis* ; Ascorbic Acid ; Atherosclerosis ; bcl-2-Associated X Protein ; Blotting, Western ; Capsaicin ; Carrier Proteins ; Cell Death ; Cholesterol ; Diet ; Down-Regulation ; Endoplasmic Reticulum Stress* ; Endoplasmic Reticulum* ; Glucose ; Hypercholesterolemia ; Lactic Acid ; Lipoproteins* ; Lymphoma, B-Cell ; Macrophages ; Methanol ; Mice ; Mice, Knockout* ; Oxidative Stress ; Phosphotransferases ; Plasma ; Prokaryotic Initiation Factor-2 ; Quercetin ; Receptors, Lipoprotein* ; Sinus of Valsalva ; Up-Regulation ; Vegetables ; Water

We report the case of a patient who experienced extreme recurrent gestational hyperlipidemia. She was diagnosed with partial lipoprotein lipase (LPL) deficiency but without an associated LPL gene mutation in the presence of the apolipoprotein E3/2 genotype. This is the first reported case of extreme gestational hyperlipidemia with a partial LPL deficiency in the absence of an LPL gene mutation and the apolipoprotein E 3/2 genotype. She was managed with strict dietary control and medicated with omega-3 acid ethyl esters. A patient with extreme hyperlipidemia that is limited to the gestational period should be considered partially LPL-deficient. Extreme instances of hyperlipidemia increase the risk of acute pancreatitis, and the effect of parturition on declining plasma lipid levels can be immediate and dramatic. Therefore, decisions regarding the timing and route of delivery with extreme gestational hyperlipidemia are critical and should be made carefully.
Acute Disease ; Adult ; Apolipoprotein E2/*genetics ; Apolipoprotein E3/*genetics ; Biological Markers/blood ; Combined Modality Therapy ; Diet, Fat-Restricted ; Fatty Acids, Omega-3/therapeutic use ; Female ; Fluid Therapy ; Genetic Predisposition to Disease ; Humans ; Hyperlipoproteinemia Type I/blood/diagnosis/enzymology/*genetics/therapy ; Lipids/blood ; Lipoprotein Lipase/genetics ; Pancreatitis/diagnosis/*etiology/therapy ; Parenteral Nutrition, Total ; Phenotype ; Pregnancy ; Pregnancy Complications/blood/diagnosis/enzymology/*genetics/therapy ; Recurrence ; Tomography, X-Ray Computed ; Treatment Outcome